-
公开(公告)号：WO2007044616A3
公开(公告)日：2007-07-12
申请号：PCT/US2006039306
申请日：2006-10-06
Applicant: XENCOR INC , LAZAR GREGORY ALAN , DESJARLAIS JOHN R , HAMMOND PHILIP W , CARMICHAEL DAVID F , CHEN BAO-LU , CHU SEUNG Y , KARKI SHER BAHADUR
Inventor： LAZAR GREGORY ALAN , DESJARLAIS JOHN R , HAMMOND PHILIP W , CARMICHAEL DAVID F , CHEN BAO-LU , CHU SEUNG Y , KARKI SHER BAHADUR
IPC: C07K16/28 , A61K39/395 , A61P35/02
CPC classification number: C07K16/2878 , C07K2317/24 , C07K2317/72 , C07K2317/732
Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcgR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
Abstract translation: 靶向CD30的抗体，其中所述抗体相对于亲本抗体包含至少一个修饰，并且与亲本抗体相比，抗体以对FcgR的亲和力改变或改变效应子功能的方式结合。 还公开了使用抗CD30抗体的方法。
-
2.发明申请ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE 审中-公开ANTAGONIST抗CD40单克隆抗体及其使用方法
公开(公告)号：WO2005044854A2
公开(公告)日：2005-05-19
申请号：PCT/US2004/037152
申请日：2004-11-04
Applicant: CHIRON CORPORATION , LONG, Li , LUQMAN, Mohammad , YABANNAVAR, Asha , ZAROR, Isabel , CHEN, Bao-Lu , LU, Xiaofeng , LEE, Sang, Hoon , HURST, Deborah
Inventor： LONG, Li , LUQMAN, Mohammad , YABANNAVAR, Asha , ZAROR, Isabel , CHEN, Bao-Lu , LU, Xiaofeng , LEE, Sang, Hoon , HURST, Deborah
IPC: C07K16/00
CPC classification number: C07K16/2878 , A61K38/2013 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: Methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40expressing cells, such as B cells.
Abstract translation: 提供了通过CD40表达细胞上的CD40信号传导介导的治疗疾病的治疗方法。 所述方法包括向有需要的患者施用治疗有效量的拮抗性抗CD40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有显着的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时，其表现出拮抗剂活性。 抗CD40抗体或其抗原结合片段的拮抗作用有益地抑制人CD40表达细胞如B细胞的增殖和/或分化。
-
3.发明申请STABILIZED LYOPHILIZED COMPOSITIONS COMPRISING TISSUE FACTOR PATHWAY INHIBITOR OR TISSUE FACTOR PATHWAY INHIBITOR VARIANTS 审中-公开包含组织因子途径抑制剂或组织因子途径抑制剂变体的稳定化LYOPHILED组合物
公开(公告)号：WO2004062646A1
公开(公告)日：2004-07-29
申请号：PCT/US2004000235
申请日：2004-01-08
Applicant: CHIRON CORP , CHEN BAO-LU , HORA MANINDER
Inventor： CHEN BAO-LU , HORA MANINDER
CPC classification number: A61K9/19 , A61K38/57 , A61K47/183 , A61K47/26
Abstract: Lyophilized compositions of TFPI or a TFPI variant suitable for long-term storage can be formed by lyophilizing an aqueous formulation of the TFPI or TFPI variant having a pH from about 4 to about 8 with a carbohydrate or amino acid glass forming agent. These lyophilized compositions are stable for greater than three months when stored at 40°C.
Abstract translation: 通过用碳水化合物或氨基酸玻璃形成剂将具有pH约4至约8的TFPI或TFPI变体的水性制剂冻干，可以形成适于长期储存的TFPI或TFPI变体的冻干组合物。 这些冻干组合物在40℃储存时稳定3个月以上。
-
4.发明申请
公开(公告)号：WO9611949A3
公开(公告)日：1996-12-12
申请号：PCT/IB9500971
申请日：1995-10-12
Applicant: AMGEN INC , MORRIS CHARLES F , KENNEY WILLIAM C , CHEN BAO LU , HSU ERIC W
Inventor： MORRIS CHARLES F , KENNEY WILLIAM C , CHEN BAO-LU , HSU ERIC W
IPC: A61K9/08 , A61K38/00 , A61K38/18 , A61K38/22 , A61P1/02 , A61P1/04 , A61P1/16 , A61P3/08 , A61P3/10 , A61P11/00 , A61P17/00 , A61P27/02 , A61P27/16 , A61P29/00 , A61P43/00 , C07K14/475 , C07K14/50 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02
CPC classification number: A61K38/1825 , C07K14/50
Abstract: The present invention concerns polypeptide analogs of a potent mitogen of non-fibroblast epithelial cell growth, keratinocyte growth factor (KGF) having up to the first 24 N-terminal amino acids modified wherein cysteine residues corresponding to amino acid positions 1 and 15 of the KGF [amino acid positions 32 and 46 of SEQ ID No:2, (Cys1 and Cys15, respectively)] are deleted or substituted with another amino acid. Also disclosed are nucleic acid molecules encoding such analogs, as well as methods for using such analogs to stimulate non-fibroblast epithelial cell proliferation.
-
5.发明申请
公开(公告)号：WO2005044854A3
公开(公告)日：2005-08-11
申请号：PCT/US2004037152
申请日：2004-11-04
Applicant: CHIRON CORP , LONG LI , LUQMAN MOHAMMAD , YABANNAVAR ASHA , ZAROR ISABEL , CHEN BAO-LU , LU XIAOFENG , LEE SANG HOON , HURST DEBORAH
Inventor： LONG LI , LUQMAN MOHAMMAD , YABANNAVAR ASHA , ZAROR ISABEL , CHEN BAO-LU , LU XIAOFENG , LEE SANG HOON , HURST DEBORAH
CPC classification number: C07K16/2878 , A61K38/2013 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: Methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40expressing cells, such as B cells.
Abstract translation: 提供了用于治疗由表达CD40的细胞上的CD40信号传导介导的疾病的治疗方法。 该方法包括向有需要的患者施用治疗有效量的拮抗性抗-CD40抗体或其抗原结合片段。 拮抗性抗CD40抗体或其抗原结合片段没有显着的激动剂活性，但当抗体结合表达人CD40的细胞上的CD40抗原时表现出拮抗剂活性。 抗CD40抗体或其抗原结合片段的拮抗剂活性有益地抑制人CD40表达细胞如B细胞的增殖和/或分化。
-
Patent Agency Ranking
公开(公告)号：WO1996040784A3
公开(公告)日：1996-12-19
申请号：PCT/US1996009980
申请日：1996-06-07
Applicant: CHIRON CORPORATION , G.D. SEARLE & CO. , DORIN, Glenn, J. , ARVE, Bo, H. , PATTISON, Gregory, L. , HALLENBECK, Robert, F. , JOHNSON, Kirk , CHEN, Bao-Lu , RANA, Rajsharan, K. , HORA, Maninder, S. , MADANI, Hassan , GUSTAFSON, Mark, E. , TSANG, Michael , BILD, Gary, S. , JOHNSON, Gary, V.
Inventor： CHIRON CORPORATION , G.D. SEARLE & CO.
IPC: C07K14/81
-
公开(公告)号：WO9640784A2
公开(公告)日：1996-12-19
申请号：PCT/US9609980
申请日：1996-06-07
Applicant: CHIRON CORP , SEARLE & CO , DORIN GLENN J , ARVE BO H , PATTISON GREGORY L , HALLENBECK ROBERT F , JOHNSON KIRK , CHEN BAO LU , RANA RAJSHARAN K , HORA MANINDER S , MADANI HASSAN , GUSTAFSON MARK E , TSANG MICHAEL , BILD GARY S , JOHNSON GARY V
Inventor： DORIN GLENN J , ARVE BO H , PATTISON GREGORY L , HALLENBECK ROBERT F , JOHNSON KIRK , CHEN BAO-LU , RANA RAJSHARAN K , HORA MANINDER S , MADANI HASSAN , GUSTAFSON MARK E , TSANG MICHAEL , BILD GARY S , JOHNSON GARY V
IPC: A23L1/00 , A23L1/0522 , A23L1/068 , A23L1/16 , A23L1/18 , A23L1/187 , A23L1/19 , A23L1/212 , A23L1/217 , A61K9/00 , A61K9/08 , A61K38/00 , A61K38/57 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/20 , A61K47/22 , A61K47/26 , A61K47/30 , A61K47/34 , A61K47/36 , A61P7/02 , A61P7/08 , A61P43/00 , C07K1/02 , C07K1/113 , C07K14/81
CPC classification number: C07K14/475 , A23L7/111 , A23L7/165 , A23L9/10 , A23L9/22 , A23L19/09 , A23L19/18 , A23L21/15 , A23L29/212 , A23L29/219 , A23P20/12 , A61K9/0019 , A61K9/08 , A61K38/57 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/36 , C07K1/1136 , C07K14/8114 , Y10S514/97 , Y10S514/973
Abstract: A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.
Abstract translation: 改变蛋白质溶解度的方法使用聚离子聚合物。 这些促进蛋白质的溶解，配制，纯化和重折叠，特别是不正确折叠的蛋白质和聚集的蛋白质。 描述了适合配制TFPI的组合物。 所述组合物允许以高于0.2mg / mL和高于10mg / mL的浓度制备药学上可接受的TFPI组合物。
-
公开(公告)号：WO2007124299A8
公开(公告)日：2008-11-06
申请号：PCT/US2007066757
申请日：2007-04-17
Applicant: NOVARTIS AG , XOMA TECHNOLOGY LTD , LU XIAOFENG , CHEN BAO-LU , ARAYA KIDISTI , OKHAMAFE AUGUSTUS
Inventor： LU XIAOFENG , CHEN BAO-LU , ARAYA KIDISTI , OKHAMAFE AUGUSTUS
IPC: C07K16/28
CPC classification number: C07K16/2878 , C07K2317/24 , C07K2317/34 , C07K2317/73 , C07K2317/76 , C07K2317/94
Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti- CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody -containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.
Abstract translation: 提供了包含作为治疗或预防活性组分的拮抗性抗CD40抗体的稳定液体药物组合物以及可用于其制备的方法。 这些组合物包含拮抗性抗-CD40抗体，将组合物的pH保持在约pH5.0与约pH7.0之间的缓冲剂，和足以使液体组合物接近等渗的量的精氨酸-HCl。 本发明的含稳定液体拮抗剂抗-CD40抗体的药物组合物可用于治疗增殖性疾病和具有自身免疫和/或炎症成分的疾病的方法。
-
公开(公告)号：WO2007124299A2
公开(公告)日：2007-11-01
申请号：PCT/US2007/066757
申请日：2007-04-17
Applicant: NOVARTIS AG , XOMA TECHNOLOGY LTD. , LU, Xiaofeng , CHEN, Bao-Lu , ARAYA, Kidisti , OKHAMAFE, Augustus
Inventor： LU, Xiaofeng , CHEN, Bao-Lu , ARAYA, Kidisti , OKHAMAFE, Augustus
CPC classification number: C07K16/2878 , C07K2317/24 , C07K2317/34 , C07K2317/73 , C07K2317/76 , C07K2317/94
Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti- CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody -containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.
Abstract translation: 提供了包含拮抗性抗CD40抗体作为治疗或预防活性成分的稳定的液体药物组合物和可用于其制备的方法。 这些组合物包含拮抗性抗-CD40抗体，保持组合物的pH在约pH5.0和约pH7.0之间的缓冲剂和足以使液体组合物接近等渗的精氨酸-HCl的量。 本发明的稳定的液体拮抗剂抗CD40抗体的药物组合物可用于治疗具有自身免疫和/或炎性成分的增殖性疾病和疾病的方法。
-
公开(公告)号：WO1996011951A2
公开(公告)日：1996-04-25
申请号：PCT/US1995013075
申请日：1995-10-12
Applicant: AMGEN INC. , CHEN, Bao-Lu , ARAKAWA, Tsutomu
Inventor： AMGEN INC.
IPC: C07K14/50
Abstract: Novel analogs of proteins of KGF are provided comprising a charge-change by the deletion or substitution of one or more of amino acid residues 41-154 of Figure 2 (amino acids 72-185 of SEQ ID NO:2). These analogs are more stable than the corresponding parent molecule KGF.
Abstract translation: 提供KGF蛋白质的新型类似物，包括通过图2的氨基酸残基41-154（SEQ ID NO：2的氨基酸72-185）的一个或多个缺失或取代的电荷变化。 这些类似物比相应的母体分子KGF更稳定。
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.013 seconds)
